Telmisartan for system suitability

European Pharmacopoeia (EP) Reference Standard

Telmisartan, BIBR 277, 4′[(1,4′-Dimethyl-2′-propyl[2,6′-bi-1H-benzimidazol]-1′-yl)methyl][1,1′-biphenyl]-2-carboxylic acid
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:


pharmaceutical primary standard





Featured Industry

Pharmaceutical (small molecule)



SMILES string




InChI key


Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Biochem/physiol Actions

Telmisartan is a non-peptide AT1 angiotensin receptor antagonist.


Unit quantity: 0.26 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.


Other Notes

Sales restrictions may apply.


13 - Non Combustible Solids

WGK Germany


Flash Point F

Not applicable

Flash Point C

Not applicable

Certificate of Analysis

Certificate of Origin

Bodh I Jugdutt
Clinical interventions in aging, 5, 403-416 (2010-12-15)
Elderly patients (age ≥ 65 years) with hypertension are at high risk for vascular complications, especially when diabetes is present. Antihypertensive drugs that inhibit the renin-angiotensin system have been shown to be effective for controlling blood pressure in adult and...
Bryan Williams et al.
Hypertension (Dallas, Tex. : 1979), 61(6), 1168-1176 (2013-05-01)
Elevated brachial blood pressure (BP) is associated with increased cardiovascular risk and predicts morbidity and mortality in humans. Recently, 24-hour ambulatory BP monitoring and assessment of central aortic BP have been introduced to improve BP phenotyping. The Ambulatory Central Aortic...
Anna Olverling et al.
Clinical science (London, England : 1979), 125(9), 433-438 (2013-05-30)
Diabetic patients are often treated with an ACEi (angiotensin-converting enzyme inhibitor) or angiotensin receptor antagonist against hypertension or albuminuria. These drugs also have a positive impact on glucose tolerance, but the mechanism for this remains elusive. Hypothesizing a positive non-additive...
Dominik Wincewicz et al.
Pharmacological reports : PR, 66(3), 436-441 (2014-06-07)
The potential effect of chronic treatment with telmisartan, an angiotensin type 1 receptor blocker (ARB) and partial agonist of peroxisome proliferator--activated receptor γ (PPARγ), on stress-related disorders is a matter of considerable interest. The existing data suggest that angiotensin II...
Mijeong Son et al.
Clinical therapeutics, 36(8), 1147-1158 (2014-07-07)
Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and telmisartan, an angiotensin receptor blocker, are commonly prescribed in combination for the treatment of dyslipidemia accompanied by hypertension. However, the nature of the pharmacokinetic interaction between the 2 drugs is not clearly...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service